Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Investigation of the Genetic Factors Underlying Severe Adverse Drug Reactions in Paediatric Cancer Patients

FY 2020-21

Summary
Adverse Drug Reactions (ADRs) represent the 5th leading cause of death in North America and cost between $30-130 billion healthcare dollars each year. Certain genetic differences can make a person more or less likely to suffer from an ADR. My research team at the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) works to reduce the occurrence of permanent disability and deaths related to ADRs as well as develop predictive genetic tests for children who may be at higher risk. This is done in a three step process-first is to perform large-scale genetic testing between children who have suffered an ADR vs. those who have not. Second is to replicate any significant genetic findings in a different cohort of patients, these genetic findings are also known as genetic variants. Finally, is where my research comes in-functionally validating the genetic variants by elucidating the mechanism by which they confer an increased risk for an ADR. Currently, I am working on a project to discover how the presence of a specific genetic variant for a drug metabolizing enzyme-known as UGT1A6-increases a child's susceptibility for an unfortunately common ADR known as anthracycline-induced cardiotoxicity. I use novel techniques developed to express the variant in cells grown in our lab and then treat them with an anthracycline known as doxorubicin-a widely used chemotherapy drug. When I confirm this specific genetic variant makes a patient more susceptible to the cardiotoxic effects of doxorubicin, it would allow us to integrate this knowledge into the Canadian healthcare system. Genetic testing prior to drug treatment would significantly decrease the prevalence of ADRs to both save healthcare dollars and most importantly, alleviate suffering amongst paediatric cancer patients.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449809
Name
Morrison Alexander J
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigation of the Genetic Factors Underlying Severe Adverse Drug Reactions in Paediatric Cancer Patients
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anthracycline; Cancer; Cardiotoxicity; Drug Effectiveness; Drug Safety; Functional Validation; Genetic Testing; Gwas; Paediatric; Pharmacogenomics
Abstract
Adverse Drug Reactions (ADRs) represent the 5th leading cause of death in North America and cost between $30-130 billion healthcare dollars each year. Certain genetic differences can make a person more or less likely to suffer from an ADR. My research team at the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) works to reduce the occurrence of permanent disability and deaths related to ADRs as well as develop predictive genetic tests for children who may be at higher risk. This is done in a three step process-first is to perform large-scale genetic testing between children who have suffered an ADR vs. those who have not. Second is to replicate any significant genetic findings in a different cohort of patients, these genetic findings are also known as genetic variants. Finally, is where my research comes in-functionally validating the genetic variants by elucidating the mechanism by which they confer an increased risk for an ADR. Currently, I am working on a project to discover how the presence of a specific genetic variant for a drug metabolizing enzyme-known as UGT1A6-increases a child's susceptibility for an unfortunately common ADR known as anthracycline-induced cardiotoxicity. I use novel techniques developed to express the variant in cells grown in our lab and then treat them with an anthracycline known as doxorubicin-a widely used chemotherapy drug. When I confirm this specific genetic variant makes a patient more susceptible to the cardiotoxic effects of doxorubicin, it would allow us to integrate this knowledge into the Canadian healthcare system. Genetic testing prior to drug treatment would significantly decrease the prevalence of ADRs to both save healthcare dollars and most importantly, alleviate suffering amongst paediatric cancer patients.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Morrison, Alexander J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~